MRKR · NASDAQ · Biotechnology

Marker Therapeutics (MRKR)

Develops non-genetically modified multi-antigen T-cell therapies for lymphoma, pancreatic cancer, AML, and MDS.

$1.23
vs last close+0.02 (+2.08%)